Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12

Harrison, Chirstine J., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Moorman, Anthony V., Grimwade, David J., Hann, Ian, Webb, David K. H., Wheatley, Keith, de Graaf, Siebold S. N., van den Berg, Eva, Burnett, Alan Kenneth and Gibson, Brenda E. S. 2010. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. Journal of Clinical Oncology 28 (16) , pp. 2674-2681. 10.1200/JCO.2009.24.8997

Full text not available from this repository.

Abstract

Purpose Karyotype is an independent indicator of prognosis in acute myeloid leukemia (AML) that is widely applied to risk-adapted therapy. Because AML is rare in children, the true prognostic significance of individual chromosomal abnormalities in this age group remains unclear. Patients and Methods This cytogenetic study of 729 childhood patients classified them into 22 subgroups and evaluated their incidence and risk. Results Rearrangements of 11q23 were the most frequent abnormality found in approximately 16% of patients, with 50% of these in infants. The outcome for all patients with 11q23 abnormalities was intermediate; no difference was observed for those with t(9;11)(p21-22;q23). The core binding factor leukemias with the translocations t(8;21)(q22;q22) and inv(16)(p13q22) occurred at incidences of 14% and 7%, respectively, predominantly in older children, and their prognosis was favorable. An adverse outcome was observed in patients with monosomy 7, abnormalities of 5q, and t(6;9)(p23;q34). Abnormalities of 3q and complex karyotypes, in the absence of favorable-risk features, have been associated with an adverse outcome in adults, but the results were not significant in this childhood series. However, the presence of 12p abnormalities predicted a poor outcome. Conclusion Because the spectrum of chromosomal changes and their risk association seem to differ between children and adults with AML, biologic differences are emerging, which will contribute to the redefinition of risk stratification for different age groups in the future.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	Q Science > QH Natural history > QH426 Genetics R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Publisher:	American Society of Clinical Oncology
ISSN:	0732-183X
Last Modified:	20 Oct 2022 08:41
URI:	https://orca.cardiff.ac.uk/id/eprint/29238

Citation Data

Cited 216 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item